---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-028704"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:34:25.227353+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Iovance reports $444M net loss for 2023; Amtagvi approved and launched Feb 2024

## Summary
- FDA approved Amtagvi (lifileucel) on Feb 16, 2024 — first T cell therapy for a solid tumor (advanced melanoma).
- Net loss $444.0M ($1.89/share) for 2023 vs $395.9M ($2.49/share) in 2022; revenue $1.2M (first Proleukin sales).
- Cash $346.3M at Dec 31, 2023; post Feb 2024 equity raise ~$485.2M, expected to fund operations into H2 2025.
- ~30 U.S. ATCs onboarded; ~50 expected by May 2024; at least 20 patients in process since approval.
- MAA for EU expected H1 2024; UK and Canada submissions H2 2024; clinical hold on IOV-LUN-202 NSCLC trial.

## SEC filing metadata
- accession: 0001104659-24-028704
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/0001104659-24-028704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/tm247491d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-028704
- JSON: https://secwatch.observer/filing/0001104659-24-028704.json
- Plain text: https://secwatch.observer/filing/0001104659-24-028704.txt

## Key facts
- Earnings Releases
  IOVANCE BIOTHERAPEUTICS, INC. reported fourth quarter ended December 31, 2023 results: net income Net loss for the fourth quarter ended December 31, 2023, was $116.4 million, EPS $0.45 per share.
  - Period: fourth quarter ended December 31, 2023
  - Net income: Net loss for the fourth quarter ended December 31, 2023, was $116.4 million
  - EPS: $0.45 per share
  - Result: reported results
  source text: Net loss for the fourth quarter ended December 31, 2023, was $116.4 million, or $0.45 per share, compared to a net loss of $105.3 million, or $0.64 per share, for the fourth quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/0001104659-24-028704-index.htm
- Earnings Releases
  IOVANCE BIOTHERAPEUTICS, INC. reported year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $444.0 million, EPS $1.89 per share.
  - Period: year ended December 31, 2023
  - Net income: Net loss for the year ended December 31, 2023 was $444.0 million
  - EPS: $1.89 per share
  - Result: reported results
  source text: Net loss for the year ended December 31, 2023 was $444.0 million, or $1.89 per share, compared to a net loss of $395.9 million, or $2.49 per share, for the year ended Dec
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/0001104659-24-028704-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.